Smac(second mitochondria-derived activator of Caspase)是一种内源性促进细胞凋亡的蛋白,主要通过拮抗凋亡抑制因子(inhibitor of apoptosis proteins,IAPs)对Caspase的抑制,以及促进Caspase的催化活性从而促进凋亡,并可通过与IAPs...Smac(second mitochondria-derived activator of Caspase)是一种内源性促进细胞凋亡的蛋白,主要通过拮抗凋亡抑制因子(inhibitor of apoptosis proteins,IAPs)对Caspase的抑制,以及促进Caspase的催化活性从而促进凋亡,并可通过与IAPs的作用参与NF-кB的调控。IAPs在肿瘤的发生、迁移以及耐药、辐射抗性的形成中发挥重要的作用。肿瘤细胞中IAPs的高表达与其抵抗凋亡的作用相关。因此,探究Smac对IAPs的拮抗作用和对Caspase的激活机制,能够进一步阐明肿瘤细胞抗凋亡机制和其他死亡途径的逃逸机制。阐述了Smac蛋白的结构、与IAPs的相互作用以及Smac模拟物作为肿瘤放化疗增敏剂的研究。展开更多
Objective： To investigate the expressions of vascular endothelial growth factor （VEGF） and proliferating cell nuclear antigen （Ki-67） in patients with rectal adenocarcinoma and their associations with neoadjuvant...Objective： To investigate the expressions of vascular endothelial growth factor （VEGF） and proliferating cell nuclear antigen （Ki-67） in patients with rectal adenocarcinoma and their associations with neoadjuvant therapy. Methods： The expressions of Ki-67 and VEGF in 32 cases of rectal adenocarcinoma, including both pretreatment tumor biopsies and postoperative specimen, were detected by immunohistochemistry using specific antibodies, and were correlated with clinicopathological factors. Results： The intensity of VEGF staining was significantly correlated with lymph nodal metastasis （P =0.033）, depth of tumor invasion （P =0.007） and tumor stage （P= 0.016）, but not with histological types, tumor sizes, patients＇ ages and genders （P 〉 0.05）. Low level of VEGF expression had significant correlation with the high sensitivity of response to neoadjuvant therapy （P = 0.016）. The transient increase of VEGF expression could be seen after neoadjuvant therapy （P = 0.035）. Ki-67 labeling index （Ki-67-LI） was significantly correlated with lymph node metastasis （P = 0.028）, but not correlated to tumor sizes, patients＇ ages and genders （P 〉 0.05）. Tumors with lower Ki-67-LI were more sensitive to neoadjuvant therapy （P = 0.032）. The Ki-67 level decreased after neoadjuvant therapy, but no statistical significance was found （P 〉 0.05）. Conclusion： Our results demonstrate that the expression of VEGF and Ki-67 in pretreatment rectal adenocarcinoma biopsies may be predictive of tumor response to neoadjuvant therapy.展开更多
文摘Smac(second mitochondria-derived activator of Caspase)是一种内源性促进细胞凋亡的蛋白,主要通过拮抗凋亡抑制因子(inhibitor of apoptosis proteins,IAPs)对Caspase的抑制,以及促进Caspase的催化活性从而促进凋亡,并可通过与IAPs的作用参与NF-кB的调控。IAPs在肿瘤的发生、迁移以及耐药、辐射抗性的形成中发挥重要的作用。肿瘤细胞中IAPs的高表达与其抵抗凋亡的作用相关。因此,探究Smac对IAPs的拮抗作用和对Caspase的激活机制,能够进一步阐明肿瘤细胞抗凋亡机制和其他死亡途径的逃逸机制。阐述了Smac蛋白的结构、与IAPs的相互作用以及Smac模拟物作为肿瘤放化疗增敏剂的研究。
文摘Objective： To investigate the expressions of vascular endothelial growth factor （VEGF） and proliferating cell nuclear antigen （Ki-67） in patients with rectal adenocarcinoma and their associations with neoadjuvant therapy. Methods： The expressions of Ki-67 and VEGF in 32 cases of rectal adenocarcinoma, including both pretreatment tumor biopsies and postoperative specimen, were detected by immunohistochemistry using specific antibodies, and were correlated with clinicopathological factors. Results： The intensity of VEGF staining was significantly correlated with lymph nodal metastasis （P =0.033）, depth of tumor invasion （P =0.007） and tumor stage （P= 0.016）, but not with histological types, tumor sizes, patients＇ ages and genders （P 〉 0.05）. Low level of VEGF expression had significant correlation with the high sensitivity of response to neoadjuvant therapy （P = 0.016）. The transient increase of VEGF expression could be seen after neoadjuvant therapy （P = 0.035）. Ki-67 labeling index （Ki-67-LI） was significantly correlated with lymph node metastasis （P = 0.028）, but not correlated to tumor sizes, patients＇ ages and genders （P 〉 0.05）. Tumors with lower Ki-67-LI were more sensitive to neoadjuvant therapy （P = 0.032）. The Ki-67 level decreased after neoadjuvant therapy, but no statistical significance was found （P 〉 0.05）. Conclusion： Our results demonstrate that the expression of VEGF and Ki-67 in pretreatment rectal adenocarcinoma biopsies may be predictive of tumor response to neoadjuvant therapy.
